Navigation Links
Jiangbo Pharmaceuticals Reports Results for the Third Quarter of its Fiscal Year 2009
Date:5/18/2009

LAIYANG, China, May 18 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (''Jiangbo'' or the ''Company''), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced its financial results for the third quarter ended March 31, 2009 of its fiscal year 2009.

    Third Quarter of Fiscal Year 2009 Highlights
    -- Total revenue, which reflects newly associated expense restructuring,
       was $25.7 million, compared to $28.1 million in the corresponding
       quarter of 2008
    -- Gross profit was $18.9 million, compared to $21.8 million in the
       corresponding quarter of 2008, and gross margin was 73.4% compared to
       77.4% in the corresponding quarter of 2008
    -- Operating income was $13.3 million, a 53.6% increase from $8.7 million
       for the three months ended March 31, 2008
    -- Net income was $8.9 million, or $0.44 per fully diluted share, up from
       $4.5 million, or $0.46 per fully diluted share, for the three months
       ended March 31, 2008
    -- Non-GAAP adjusted net income was $10.0 million, or $0.97 per weighted
       average share for the three months ended March 31, 2009, up 66.5% from
       non-GAAP adjusted net income of $6.0 million, or $0.61 per weighted
       average number of shares, for the quarter ended March 31, 2008
    -- Acquired Shandong Hongrui Pharmaceutical Factory ("Hongrui") for
       approximately $11.2 million consisting of RMB58.6 million in cash
       (approximately $8.6 million) and 643,651 shares of Jiangbo's common
       stock amounting to approximately $2.6 million
    -- Obtained the legal rights to manufacture and distribute Hongrui's 22
       Traditional Chinese Medicines
    -- Restructured its sales network to distribute products through 28 large
       regional distributors
    -- Changed the corporate name from Genesis Pharmaceuticals Enterprises,
       Inc. to ''Jiangbo Pharmaceuticals, Inc.'' and its stock symbol from
       ''GNPH'' to ''JGBO''.
    -- Launched a new website: http://www.jiangbopharma.com/

''Jiangbo had strong financial performance in the third quarter of our fiscal year 2009. Significant increases in sales of Radix Isatidis Dispersible Tablets and Baobaole Chewable Tablets, both of which are Traditional Chinese Medicines, contributed to revenue and operating income growth,'' said Mr. Wubo Cao, Chairman and Chief Executive Officer of Jiangbo.

Third Quarter of Fiscal Year 2009 Results

Total revenue for the three months ended March 31, 2009 was $25.7 million, compared to $28.1 million for the three months ended March 31, 2008.

In January 2009, Jiangbo restructured its distribution and sales system to concentrate on using 28 large independent regional distributors. The independent distributors agreed to take on higher direct marketing and sales expenses if they received lower unit prices for the Company's products. The Company lowered its per unit prices for its three major products to the independent distributors. Jiangbo's new strategy is to use independent distributors for the distribution and sale of its three major products in order to gain access to their knowledge of and access to specific local markets.

The Company lowered its unit prices charged to independent distributors by an average of 26.0% for Clarithromycin Sustained-released tablets, Itopride Hydrochloride granules and Baobaole chewable tablets. The decrease in revenue from lower prices for these three major products was partially offset by an increase in sales revenue from Radix Isatidis Dispersible tablets, a new product launched in December 2008, and other Traditional Chinese Medicines acquired from Hongrui in January 2009.

Sales volume for Clarithromycin Sustained-released tablets and Baobaole chewable tables was higher in the three months ended March 31, 2009 than in the three months ended March 31, 2008. Clarithromycin Sustained-released tablets, Itopride hydrochloride granules and Baobaole chewable accounted for approximately 88.6 % of the total revenue in the three months ended March 31, 2009. Sales volume for Radix Isatidis Dispersible tablets grew throughout the three months ended March 31, 2009.

Gross profit in the third quarter of fiscal year 2009 was $18.9 million, compared to $21.8 million in the prior year's corresponding period. Gross margin was 73.4%, compared to 77.4% in the prior year's corresponding period because of the impact of lower unit sale prices for the Company's three major products.

Research and development costs were $1.1 million for the three months ended March 31, 2009, compared to $1.0 million for the three months ended March 31, 2008.

Selling, general and administrative expenses were $4.5 million for the three months ended March 31, 2009, a decrease of 63.1% from $12.1 million in the three months ended March 31, 2008. Salaries, wages and related benefits decreased by 73.1% from $7.5 million for the three months ended March 31, 2008 to $2.0 million for the three months ended March 31, 2009 primarily because of the significant decrease in commissions paid to the Company's sales representatives. Overall sales commissions declined as a result of cost savings associated with the increased use of 28 independent distributors.

Income from operations was $13.3 million for the three months ended March 31, 2009, a 53.6% increase from $8.7 million for the three months ended March 31, 2008.

Other expense, comprised primarily of interest earned, interest owed and amortized debt discount, was $1.1 million compared to $2.0 million for the three months ended March 31, 2008.

Net income for the three months ended March 31, 2009 was $8.9 million, $0.44 diluted earnings per share, compared to $4.5 million, and $0.46 diluted earnings per share, for the three months ended March 31, 2008.

Excluding a loss from discontinued operations of $103,008, a gain on trading securities of $204,134, and amortization of debt discount and issuance costs related to convertible debentures of $1.2 million, non-GAAP adjusted net income for the three months ended March 31, 2008 was $10.0 million, $0.97 per share, compared to adjusted net income of $6.0 million, $0.61 per share, for the three months ended March 31, 2008.

Nine Month Operating Highlights

Total revenue for the nine month period ended March 31, 2009 was $86.2 million, up 21.0% from $71.3 million for the nine month period ended March 31, 2008.

Gross profit for the nine month period ended March 31, 2009 totaled $66.5 million, up 24.2% from $53.5 million for the nine month period ended March 31, 2008. Gross profit margin was 77.1% for the nine month period ended March 31, 2009, compared to 75.1% for the corresponding period in 2008.

Operating income for the nine month period ended March 31, 2009 totaled $32.1 million, a 45.3% increase from $22.1 million in the corresponding period in 2008. The Company's operating margin increased to 37.2% from 31.0% compared to the same period in 2008, as result of the Company's continuing efforts to reduce its expenses and control its costs.

Net income for the nine month period ended March 31, 2009 was $17.4 million, $1.27 diluted earnings per share, compared to $12.9 million, $1.14 diluted earnings per share, for the corresponding period in 2008. Total shares outstanding as of May 14, 2009 were 10,351,448.

Excluding a loss from discontinued operations of $1.7 million, a loss on trading securities of $1.3 million, and amortization of debt discount and issuance costs related to convertible debentures of $3.2 million, non-GAAP adjusted net income for the nine month period ended March 31, 2008 was $23.5 million, $2.37 per share, compared to adjusted net income of $14.8 million, $2.28 per share, for the nine month period ended March 31, 2008.

Financial Condition

As of March 31, 2009, the Company had $86.1 million in cash and restricted cash. Working capital was $85.6 million, up from $72.5 million as of June 30, 2008. Current liabilities were $27.4 million and convertible debt, net of $29.8 million discount, was $5.0 million. Shareholders' equity was $113.9 million, compared to $95.5 million as of June 30, 2008.

The Company generated $41.1 million in cash flow from operating activities in the first nine months of its fiscal year 2009, compared to $17.7 million for the first nine months of its fiscal year 2008. The Company believes that its strong cash position will sustain its future working capital needs and successfully implement its growth strategies which include the expansion of manufacturing facilities.

Recent Events

On April 23, 2009, the Company announced that it changed its corporate name from ''Genesis Pharmaceuticals Enterprises, Inc.'' to ''Jiangbo Pharmaceuticals, Inc.'' to align the name of the public company with the name of its products. Management wants to associate the brand name ''Jiangbo'' with the Company while it continues to develop its brand and corporate image, and expands its product line.

Jiangbo's stock started trading on the Over the Counter Bulletin Board under ticker symbol "JGBO" on May 12, 2009. The Company's shares ceased trading under the ticker symbol "GNPH" at the close of business on May 11, 2009. The Company's shares are identified under a new CUSIP Number: 47737 R 10 1. The Company still plans to apply to list its common stock on a senior U.S. stock exchange.

In April, the Company announced that it began marketing and selling three Traditional Chinese Medicines. They are Yi Mu Cao Gao (a motherwort herb electuary sticky syrup), Gan Mao Zhi Ke Ke Li (an antipyretic and antitussive granule), and Kang Gu Sui Yan Pian (an osteomyelitis treatment tablet). In April, Jiangbo started to produce Laiyang Pear Cough Syrup and New Compound Foliumisatidis Tablets. Laiyang Pear Cough Syrup helps relieve coughs arising from colds and other illnesses. Market feedback has shown that children like its fresh pear taste. New Compound Foliumisatidis Tablets address influenza symptoms and includes both western chemical ingredients and traditional Chinese herbs.

Sales of these five products are expected to be $2.0 million in the fourth quarter of the Company's fiscal year 2009, which ends on June 30, 2009, and an estimated $8.0 million in fiscal year 2010.

Business Outlook and Guidance

In April, the Company reaffirmed operating income guidance of $40 to $43 million for its fiscal year ending June 30, 2009, and adjusted its revenue guidance for its fiscal year ending June 30, 2009 from a range of $122 million to $130 million to a range of $111 million to $116 million. This adjustment to revenue guidance was mainly because of the Company's charging lower unit prices to the 28 independent distributors which sell and distribute the Company's three major products. The Company expects to meet or exceed its fiscal year 2009 guidance.

On April 6, 2009, China unveiled its ''Guideline of Deepening the Reform of Health Care System'' (''Guideline''), a blueprint for health care over the next decade. By 2020, the world's most populous nation plans to have a basic health care system that can provide "safe, effective, convenient and affordable" health services to urban and rural residents. The State Council announced an investment of 850 billion Yuan (US $124 billion) to implement the health care reform plan in China.

''We believe that the Chinese government's planned reforms for China's healthcare system will increase demand for Jiangbo's products because a number of Jiangbo products are used to treat common and widespread illnesses. Several of our products should be good candidates for inclusion on provincial and the national drug lists, which are used to stock clinics and hospitals. We look forward to working with the government's planned programs to help meet the needs of an increasing number of China's consumers,'' concluded Mr. Cao.

Conference Call

Jiangbo Pharmaceuticals, Inc. management will host a conference call at 9:30a.m. Eastern Time on Tuesday, May 19, 2009 to discuss financial results for the quarter ended March 31, 2009. Mr. Wubo Cao, Chairman and CEO, Mr. Haibo Xu, COO and Ms. Elsa Sung, CFO, of Jiangbo will be present for the conference call. To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time of 9:30 a.m. Eastern Time on Tuesday, May 19, 2009: (888) 481-7939. International callers should call (617) 847-8707. The Conference Passcode is 564 145 01. Replay of the conference call will be available from Tuesday, May 19, 2009 at 11:30 a.m. Eastern for 14 days. To access the replay, call (888) 286-8010. International callers should call (617) 801-6888. The Conference Passcode is: 547 268 69.

Use of Non-GAAP Financial Information

This press release includes certain financial information, adjusted net income and adjusted fully diluted earnings per share, which are not presented in accordance with GAAP. Adjusted net income was derived by taking net income and adjusting it with a loss from discontinued operations, unrealized losses on trading securities and non-cash amortization of debt discount and debt issuance costs related to convertible securities. The Company's management believes that these non-GAAP measures provide investors with a better understanding of the Company's historical results from its core business operations. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information, which is adjusted net income and adjusted earnings per share, excluding the impact of these items in this release. The non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information provided by the Company may also differ from non-GAAP information provided by other companies. A table below provides a reconciliation of the non-GAAP financial information to the nearest GAAP measure.

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Tel:   +1-954-727-8435
     Email: elsasung@jiangbo.com
     Web:  http://www.jiangbopharma.com

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com


                JIANGBO PHARMACEUTICALS, INC. AND SUBSIDIARIES
             (FORMERLY GENESIS PHARMACEUTICALS ENTERPRISES, INC.)
       CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME
                                 (UNAUDITED)

                          For the Three Months Ended For the Nine Months Ended
                                  March 31,                  March 31,
                              2009         2008         2009         2008
    REVENUES:
           Sales           $25,725,837  $26,231,191  $85,991,330  $66,648,051
           Sales-related
            parties                 --    1,869,092      243,943    4,611,849
    TOTAL REVENUE           25,725,837   28,100,283   86,235,273   71,259,900


      Cost of sales          6,853,810    5,896,113   19,705,020   16,626,461
      Cost of sales -
       related parties              --      441,709       54,500    1,117,918
    COST OF SALES            6,853,810    6,337,822   19,759,520   17,744,379

    GROSS PROFIT            18,872,027   21,762,461   66,475,753   53,515,521

    RESEARCH AND
     DEVELOPMENT EXPENSE     1,098,675      967,930    3,295,125    2,170,240

    SELLING, GENERAL AND
     ADMINISTRATIVE
     EXPENSES                4,477,356   12,136,164   31,111,752   29,269,330

    INCOME FROM OPERATIONS  13,295,996    8,658,367   32,068,876   22,075,951

    OTHER (INCOME) EXPENSE:
      Other (income)
       expense, net           (281,570)   1,244,892    1,062,959    1,217,385
      Other (income)-
       related parties         (76,552)     (27,415)    (313,276)     (80,851)
      Non-operating
       (income) expense        150,466         (529)        (471)        (232)
      Interest expense,
       net                   1,241,843      526,509    4,143,968      925,993
      Loss from
       discontinued
       operations              103,008      228,812    1,693,830      341,743
    OTHER EXPENSE, NET       1,137,195    1,972,269    6,587,010    2,404,038

    INCOME BEFORE PROVISION
     FOR INCOME TAXES       12,158,801    6,686,098   25,481,866   19,671,913

      PROVISION FOR INCOME
       TAXES                 3,302,953    2,211,265    8,093,320    6,808,625

      NET INCOME            $8,855,848   $4,474,833  $17,388,546  $12,863,288

      OTHER COMPREHENSIVE
       INCOME:
         Unrealized holding
          (loss) gain        $(200,025)   $(270,351) $(2,147,642)  $1,347,852
         Foreign currency
          translation
          adjustment          (201,173)   1,960,948      378,284    3,428,779

            COMPREHENSIVE
             INCOME         $8,454,650   $6,165,430  $15,619,188  $17,639,919


      BASIC WEIGHTED AVERAGE
       NUMBER OF SHARES     10,277,762    9,740,129    9,937,190    6,507,435


      BASIC EARNINGS PER
       SHARE                     $0.86        $0.46        $1.75        $1.98

      DILUTED WEIGHTED
       AVERAGE NUMBER OF
       SHARES               10,907,231    9,740,129   10,599,615    7,081,791


      DILUTED EARNINGS PER
       SHARE                     $0.44        $0.46        $1.27        $1.14



                JIANGBO PHARMACEUTICALS, INC. AND SUBSIDIARIES
             (FORMERLY GENESIS PHARMACEUTICALS ENTERPRISES, INC.)
                         CONSOLIDATED BALANCE SHEETS

                            A S S E T S
                                                     March 31,      June 30,
                                                       2009           2008
                                                    (Unaudited)

    CURRENT ASSETS:
     Cash                                           $82,338,527   $48,195,798
     Restricted cash                                  3,713,775     7,839,785
     Investments                                        672,682     2,055,241
     Accounts receivable, net of allowance for
      doubtful accounts of $525,268 and
      $155,662, respectively                         21,688,723    24,312,077
     Accounts receivable - related parties              187,766       673,808
     Inventories                                      3,863,947     3,906,174
     Other receivables                                   81,784       152,469
     Other receivables-related parties                  317,412            --
     Advances to suppliers and other assets             130,088     1,718,504
      Total current assets                          112,994,704    88,853,856

    PLANT AND EQUIPMENT, net                         14,162,421    11,225,844

    OTHER ASSETS:
     Restricted investments                             400,050     2,481,413
     Financing costs, net                             1,406,717     1,916,944
     Intangible assets, net                          17,404,557     9,916,801
      Total other assets                             19,211,324    14,315,158

       Total assets                                $146,368,449  $114,394,858

       L I A B I L I T I E S   A N D   S H A R E H O L D E R S'   E Q U I T Y

    CURRENT LIABILITIES:
     Accounts payable                                $5,523,666    $2,341,812
     Short term bank loans                            2,197,500     2,772,100
     Notes payable                                    3,713,775     5,843,295
     Other payables                                   4,074,203     3,671,703
     Customer deposit                                 4,102,000            --
     Other payables - related parties                   176,666       324,972
     Accrued liabilities                                754,315       173,604
     Liabilities assumed from reorganization          1,613,935     1,084,427
     Taxes payable                                    5,276,690       166,433
      Total current liabilities                      27,432,750    16,378,346

    CONVERTIBLE DEBT, net of discount $29,820,431
     and $32,499,957 as of March 31, 2009 and
     June 30, 2008, respectively                      5,019,569     2,500,043

       Total liabilities                             32,452,319    18,878,389

    COMMITMENTS AND CONTINGENCIES

    SHAREHOLDERS' EQUITY:
     Preferred stock Series ($0.001 par value;
      20,000,000 shares authorized; none issue,
      or outstanding)                                        --            --
     Common stock ($0.001 par value,
      22,500,000 and 15,000,000 shares authorized,
       respectively; 10,435,099 and 9,767,844
       shares issued and outstanding, respectively)       10,436         9,770
     Paid-in-capital                                  76,168,319    45,554,513
     Capital contribution receivable                 (27,845,000)      (11,000)
     Retained earnings                                56,390,950    39,008,403
     Statutory reserves                                3,253,878     3,253,878
     Accumulated other comprehensive income            5,931,547     7,700,905
      Total shareholders' equity                     113,916,130    95,516,469
       Total liabilities and shareholders' equity   $146,368,449  $114,394,858



               JIANGBO PHARMACEUTICALS, INC.  AND SUBSIDIARIES
             (FORMERLY GENESIS PHARMACEUTICALS ENTERPRISES, INC.)
                    CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (Unaudited)

                                                 For the Nine Months Ended
                                                         March 31,
                                                   2009              2008
    CASH FLOWS FROM OPERATING ACTIVITIES:
      Net income                               $17,388,546       $12,863,288
      Loss from discontinued operations          1,693,830           341,743
      Income from continuing operations         19,082,376        13,205,031
      Adjustments to reconcile net income
       to cash, net of acquisition
       provided by (used in) operating
       activities:
        Depreciation                               464,094           375,456
        Amortization of intangible assets          371,925           113,578
        Amortization of deferred debt
         issuance costs                            510,227            47,583
        Amortization of debt discount            2,679,526           671,296
        Bad debt expense                           368,840          (112,459)
        Gain on sale of marketable securities     (106,865)           19,819
        Unrealized loss (gain) on trading
         securities                              1,255,522         1,150,516
        Other non-cash settlement                  (20,000)               --
        Stock-based compensation                    43,340            28,750
       Changes in operating assets and
        liabilities
        Accounts receivable                      2,353,566        (7,246,740)
        Accounts receivable - related parties      488,646        (1,403,383)
        Notes receivables                               --            59,790
        Inventories                                205,471            27,542
        Other receivables                           63,170          (254,886)
        Other receivables- related parties        (317,303)          (81,384)
        Advances to suppliers and other
         assets                                  1,602,693          (391,526)
        Accounts payable                         3,171,180         1,159,105
        Accrued liabilities                        682,145           301,290
        Other payables                             194,283         2,146,659
        Other payables - related parties           (58,580)         (962,509)
        Customer deposit                         4,100,600                --
        Liabilities assumed from
         reorganization                         (1,164,323)       (1,162,133)
        Taxes payable                            5,107,831        10,006,057
            Net cash provided by
             operating activities               41,078,364        17,697,452

    CASH FLOWS FROM INVESTING ACTIVITIES:
      Cash used in acquisition                  (8,581,970)               --
      Proceeds from sale of marketable
       securities                                  167,623           605,882
      Prepayment for land use right                     --        (8,246,830)
      Cash receipt from reverse
       acquisition                                      --           534,950
      Purchase of equipment                       (130,814)         (401,302)
            Net cash used in investing
             activities                         (8,545,161)       (7,507,300)

    CASH FLOWS FINANCING ACTIVITIES:
      Restricted cash                            4,149,305        (5,361,849)
      Proceeds from sale of common stock
       and options exercised                            --           337,500
      Proceeds from sale of treasury stock              --             1,977
      Proceed from convertible debt                     --         5,000,000
      Payments on debt issuance costs                   --          (354,408)
      Payments for dividend                             --       (10,520,000)
      Proceeds from bank loans                   2,196,750         3,255,360
      Payments for bank loans                   (2,782,550)       (5,425,600)
      Proceed from officers                             --            27,128
      Proceeds from notes payable                7,009,097        10,729,040
      Principal payments on notes payable       (9,161,912)       (5,367,191)
            Net cash provided (used) in
             financing activities                1,410,690        (7,678,043)

    EFFECTS OF EXCHANGE RATE CHANGE IN CASH        198,836         1,324,727

     INCREASE (DECREASE) IN CASH                34,142,729         3,836,836

    CASH, beginning of the period               48,195,798        17,737,208

    CASH, end of the period                    $82,338,527       $21,574,044

    SUPPLEMENTAL DISCLOSURES OF CASH FLOW
     INFORMATION:
      Interest paid                             $1,130,837          $331,431
      Income taxes paid                         $4,883,039        $3,615,867
    Non-cash investing and financing
     activities:
       Common stock issued to acquire Hongrui   $2,597,132                --



          GENESIS PHARMACEUTICALS ENTERPRISES, INC. AND SUBSIDIARIES
                    RECONCILIATION OF NON-GAAP NET INCOME

                               For Three Months Ended   For Nine Months Ended
                                 March 31  March 31,     March 31    March 31
                                   2009       2008         2009        2008


    Net Income                   8,855,848  4,474,833  17,388,546  12,863,288
    Loss from discontinued
     operations                    103,008    228,812   1,693,830     341,743
    Unrealized loss (gain) on
     trading securities, net      (204,134) 1,159,409   1,255,522   1,150,516
    Amortization of debt
     discount and debt
     issuance costs related to
     convertible debentures      1,203,365    118,149   3,189,752     481,589

    Adjusted Net Income          9,958,087  5,981,203  23,527,650  14,837,136

    Basic Weight Average
     Number of Shares           10,277,762  9,740,129   9,937,189   6,507,435

    Adjusted Earnings Per
     Weighted Average Number of
     Shares                          $0.97      $0.61       $2.37       $2.28


'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
2. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
3. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
4. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
5. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
6. NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
7. BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
8. MAP Pharmaceuticals Announces Presentations at the American Thoracic Society International Conference
9. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
11. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Elizabeth Murray has always loved walking one ... with one on her shoulder and one on her arm. But she got to ... years of mitral valve prolapse. , The valves of the heart wouldn’t close properly ...
(Date:5/3/2016)... Pasadena, CA (PRWEB) , ... May 03, 2016 ... ... tuition-free, accredited American online university, has announced today the launch of its Associates ... Nobel Laureate and President Emeritus of The Rockefeller University, Dr. Torsten N. Wiesel; ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Boston Children’s Hospital ... rehearse tough medical situations or practice tricky or rare procedures in an environment that ... the SIM Center is also available to inventors and “hackers” to develop and test ...
(Date:5/3/2016)... ... 03, 2016 , ... Park Cities Pet Sitter has openings for both full-time ... 75205, 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 and 75235 zip codes. ... Plano, Preston Hollow and Park Cities areas of the Metroplex. Candidates must love ...
(Date:5/3/2016)... York, NY (PRWEB) , ... May 03, 2016 ... ... solutions for the healthcare industry, announced today that Legacy Health is expanding its ... Efficient Works platform), after a highly successful initial proof of concept. The Portland, ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 3, 2016 Intec Pharma Ltd. ... biopharmaceutical company, today announced the appointment of Pnina ... "Ms. Strauss-Levy has 15 years of experience ... an outstanding track record, having supported the advancement of ... processes in the United States ...
(Date:5/2/2016)... -- Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... Ireland 7.8 India 7.3, , Source: IMF and TechSci Research ... of Brazil , Russia , ... , registered the fastest GDP growth during the first decade of the ... recession in Brazil and Russia , ...
(Date:4/29/2016)... 2016  In the next ten years, the ... systems dependent on CRTs monitors to those reliant on ... Medical monitors and will automatically sync to existing ... foreseeable benefits to this technological advancement, it also ... to be replaced in order to be LCD ...
Breaking Medicine Technology: